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abstRact
IntroductIon: The purpose of this pilot study was to in-
vestigate whether a short prostate biparametric magnetic 
resonance imaging (bp-MRI) protocol provides a valuable 
diagnostic addition for biopsy guidance in biopsy-naive men 
with a suspicion of prostate cancer (PCa). 
MethodS: A total of 62 biopsy-naive patients referred to a 
systematic transrectal ultrasound biopsy (TRUS-bx) due to 
suspicion of PCa were prospectively enrolled. Bp-MRI was 
performed before biopsy. All lesions were scored according 
to the modified Prostate Imaging Reporting and Data Sys-
tem (PI-RADS) version 2. All patients underwent TRUS-bx 
followed by bp-MRI-guided biopsies (bp-MRI-bx) under 
MRI/TRUS image fusion from any bp-MRI suspicious lesions 
not obviously targeted by TRUS-bx. 
reSultS: PCa was found in 42 (68%) and 32 (52%) patients 
by TRUS-bx and bp-MRI-bx, respectively. Bp-MRI-bx de-
tected PCa in one patient who had been missed by TRUS-bx, 
and found the highest Gleason score (GS) in 13 (30%) pa-
tients leading to an overall GS upgrade in six (14%) patients. 
Bp-MRI missed nine patients with GS = 6 and two with a GS 
= 7 (3 + 4), all of whom were diagnosed by TRUS-bx. 
concluSIonS: Addition of bp-MRI-bx to routine TRUS-bx 
seems feasible in biopsy-naive patients and may improve the 
detection of aggressive PCa in first-round biopsies. This pilot 
study thus provides an incentive for a larger investigation. 
FundIng: Costs were covered by the Department of Radi-
ology, Herlev Hospital, Denmark.
trIal regIStratIon: This study was registered with the 
Danish Data Protection Agency (HEH-2015-054, I-Suite no: 
03775) and with the Committee for Health Research Ethics 
(no. H-15009341).
Early detection and risk evaluation of patients with pros-
tate cancer (PCa) is the key to providing the right treat-
ment at the right time. Approx. 4,400 men are diag-
nosed annually with PCa in Denmark and the incidence 
is expected to rise in coming years [1]. Transrectal ultra-
sound (TRUS) guidance of biopsies (bx) has been the pri-
mary diagnostic examination for many years. However, 
TRUS-bx suffers from a high biopsy burden, frequent 
false negative results and an erroneous estimation of 
the final pathology [2-4]. Since TRUS poorly visualises 
both any pathological changes and the anterior com-
ponents, the systematic biopsies based on TRUS may 
benefit from supporting image diagnostics. PCa typically 
presents with varying degrees of aggressiveness and 
Gleason scores (GS) and it is important to detect severe 
pathological changes early.
Multiparametric magnetic resonance imaging (mp-
MRI) has been shown to be a valuable addition to TRUS-
bx [5-7]. However, mp-MRI of the prostate is time-con-
suming. An examination time of one hour and the usage 
of intravenous contrast medium make it a less attractive 
option in a large patient population. Conceivably, it is 
feasible to shorten the examination time in patients 
with no prior biopsies and still offer an adequate exam-
in ation. Therefore, we undertook a pilot study to investi-
gate whether a biparametric MRI (bp-MRI) scanning pro-
tocol may serve as a valuable diagnostic addition to 
guide TRUS biopsies in biopsy-naive men with a suspi-
cion of PCa.
mEthOds
Invited to participate in the study were all patients re-
ferred for a TRUS-bx to the Department of Urology, Her-
lev Hospital, University of Copenhagen, Denmark, on 
Mondays, Tuesdays and Thursdays within a two-month 
period on suspicion of PCa due to either 1) a prostate-
specific antigen (PSA) > 4 ng/ml, 2) suspicious digital rec-
tal exploration (DRE), 3) earlier suspicious TRUS without 
biopsies or 4) other predisposition (e.g. family history of 
PCa).
The exclusion criteria were: 1) previous PCa diagno-
sis, 2) previous biopsies of the prostate, 3) certain types 
of implants incompatible with MRI (e.g. pacemaker),  
4) any metal implants in the pelvis (e.g. hip replacement) 
and 5) claustrophobia.
Permission for this study was granted by the Danish 
Data Protection Agency (HEH-2015-054, I-Suite no: 
03775) and by the Committee for Health Research Ethics 
(no. H-15009341).
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biparametric magnetic resonance imaging
Patients were scanned in a 3.0-T clinical MRI system (In-
genia, Philips Healthcare, Best, the Netherlands) to ac-
quire: 1) an axial T2-weighted (T2W) sequence, 2) axial 
diffusion-weighted images (DWI) with b-values of 0, 100, 
800 and 2,000. An apparent diffusion coefficient (ADC) 
map was calculated based on all acquired b-values.  
A sagittal T2W scout supported the axial sequences.  
The combined examination time was 30 minutes.
magnetic resonance image analysis
Suspicious malignant lesions in the transitional and per-
ipheral zone of the prostate were marked on the bp-MRI 
and retrospectively classified in accordance with the  
European Society of Urogenital Radiology’s (ESUR) rec-
ommended Prostate Imaging Reporting and Data System 
(PI-RADS) guidelines [8, 9]. All lesions were scored on a 
scale ranging 1-5 indicating the likelihood of malignancy 
(1 = highly unlikely; 2 = unlikely; 3 = equivocal; 4 = likely; 
5 = highly likely). However, asbp-MRI does not include 
dynamic contrast enhanced (DCE) T1W sequences, the 
scoring criteria of lesions in the peripheral zone were 
determined by the DWI and ADC map in accordance 
with PI-RADS version 2 guidelines [9].
transrectal ultrasound biopsy procedure with  
biparametric magnetic resonance imaging guidance
All patients had a DRE prior to TRUS. During TRUS, the 
prostate volume was measured (width × length × height) 
and the parenchyma was evaluated for suspicious malig-
nant areas. A Hitachi Ascendus ultrasound scanner 
(Kashiwa, Japan) and a Hitachi EUP-533 biplane trans-
ducer (Kashiwa, Japan) were used. 
Initially, all patients underwent TRUS-bx, varying 
the number of biopsy cores deemed necessary for diag-
nosis and depending on the clinical situation. Patients 
who were considered suitable for treatment with a cura-
tive intent had 6-10 standard biopsies (n = 60). Patients 
in whom PCa was highly likely based on DRE and PSA 
and who were not suitable for curative treatment had 
1-2 standard biopsies (n = 2) to confirm their diagnosis. 
The TRUS-bx operator was blinded to any bp-MRI find-
ings during the standard biopsies. Thereafter, the bp-
MRI was opened, transferred to the ultrasound machine 
via the Hitachi RVS-software and then fused with the 
TRUS image. Fusion biopsies (1-2 cores) were taken from 
each suspicious lesion marked on the bp-MRI. If bp-MRI-
suspicious lesions were placed in a region already biop-
sied by the standard biopsies, the area was omitted. All 
biopsies were taken using an end-fire technique and a 
Hitachi EUP-V53W transducer.
criteria for clinically significant prostate cancer
The following preoperative criteria were used to evalu-
ate positive TRUS-bx as clinically significant: a) a GS ≥ 7, 
b) ≥ 3 positive biopsy cores or c) cancer extension ≥ 50% 
per biopsy. Furthermore, a PSA > 10 ng/ml in combina-
tion with a GS of 6 was deemed clinically significant. On 
MRI target biopsies, the criteria were GS ≥ 7, cancer ex-
tension ≥ 50% per biopsy or a PSA > 10 ng/ml.
statistical analysis 
Clinical data including age, PSA, PSA density, number of 
bp-MRI lesions and the number of bp-MRI biopsies were 
compared based on biopsy findings using a nonparamet-
ric Wilcoxon rank sum test when possible and character-
ised using descriptive statistics. Overall, GS of TRUS-bx, 
bp-MRI biopsies and combined results were compared. 
Bp-MRI PI-RADS scores for each identified lesion were 
graphically compared with biopsy results. No statistical 
tests or calculation of sensitivity or specificity were per-
formed due to the population size and lack of a gold 
abbREviatiOns
ADC = apparent diffusion coefficient
Bp-MRI = biparametric magnetic resonance imaging
Bx = biopsy
DCE = dynamic contrast enhanced
DWI = diffusion-weighted images
ESUR = European Society of Urogenital Radiology
GS = Gleason score
HG = high grade
IG = intermediary grade
LG = low grade
mp-MRI = multiparametric magnetic resonance imaging
MRI = magnetic resonance imaging
NAD = no applicable disease
PCa = prostate cancer
PI-RADS = Prostate Imaging Reporting and Data System
PSA = prostate-specific antigen
PSAD = PSA density
PZ = peripheral zone
T2W = T2-weighted
TRUS = transrectal ultrasound
TZ = transition zone
Example of a biparametric 
magnetic resonance im-
aging (bp-MRI) showing 
axial sequences of T2-
weighted (T2W) (a), diffu-
sion-weighted images 
with b = 2,000 (b) and the 
apparent diffusion coeffi-
cient map (c) in addition 
to the sagittal T2W scout 
(d). Routine transrectal 
ultrasound biopsy found 
Gleason score (GS) = 3 + 4 
in two biopsy cores while 
a bp-MRI-guided biopsy 
from the indicated anter-
ior prostate cancer com-
ponent found GS = 5 + 3 
leading to an overall GS 
upgrade.
a
c
b
d
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standard. Patients were divided by tumour aggressive-
ness into the following groups: low grade (LG; GS ≤ 6), 
intermediary grade (IG; GS = 7) and high grade (HG; GS ≥ 
8 or any grade-5 component present).
Trial registration: Danish Data Protection Agency (HEH-
2015-054, I-Suite no: 03775) and Committee for Health 
Research Ethics (no. H-15009341).
REsUlts
A total of 67 patients were included between November 
and December 2015. Five patients were excluded due to 
comorbidity (n = 1), transport difficulties to the hospital 
(n = 3) or claustrophobia (n = 1). Demographic data are 
summarised in table 1.
Overall, PCa was detected in 43 out of the 62 pa-
tients (69%). Bp-MRI-guided biopsies were positive for 
at least one PCa lesion in 32 patients (52%), while stan-
dard TRUS-bx detected PCa in 42 patients (68%). Bp-MRI 
missed seven out of 37 (19%) patients with clinically sig-
nificant PCa. Of these, two patients had GS 7 (3 + 4) and 
five had GS 6 (3 + 3), which were deemed clinically sig-
nificant due to ≥ 3 positive biopsies. One patient had 
PCa detected only on bp-MRI biopsy of a PI-RADS 4 le-
sion showing a GS of 7 (4 + 3) in 75% of the biopsy core. 
No patients with severe malignancy PCa (GS ≥ 8) were 
missed by bp-MRI-bx. 
Bp-MRI-bx cores revealed the highest GS in 13 pa-
tients, leading to an overall GS upgrade in six (14%) pa-
tients. TRUS-bx scored the highest GS in five patients 
(16%). Of these, three patients were upgraded from a LG 
to an IG risk group, while two remained in the HG group 
with a GS ≥ 8. Bp-MRI diagnosed two patients with clin-
ically significant PCa, which would have been deemed 
insignificant based on TRUS-bx. The distribution of GS 
and patient risk stratification for TRUS-bx, bp-MRI biop-
sies and the two combined are summarised in table 2 
and table 3.
PI-RADS scores of suspicious bp-MRI lesions showed 
tablE 1
clinical characteristic negative (n = 19) Positive (n = 43) p-valuea total (n = 62)
Age, yrs, median (range) 63 (52-72) 68 (49-80) < 0.02 66 (49-80)
PSA concentration, ng/ml, median (range) 6 (1.6-20) 7.3 (1.7-85) < 0.053 6.9 (1.6-85)
Prostate volume, ml, median (range) 59 (33-99) 44 (20-105) < 0.001 49 (20-105)
PSAD, ng/ml/cm3, median (range) 0.11 (0.05-0.31) 0.19 (0.04-1.55) < 0.0001 0.15 (0.04-1.55)
Clinical T category, n (%)
T1c 14 (74) 19 (44) 33 (53)
T2a   1 (5)   7 (16)   8 (13)
T2b   0   6 (14)   6 (10)
T2c   0   2 (5)   2 (3)
T3a   0   7 (16)   7 (11)
Tx   4 (21)   2 (5)   6 (10)
Nonpalpable tumour, cT1c, n (%) 14 (74) 19 (44) 33 (53)
Palpable tumour, cT2-cT3, n (%) 1 (5) 23 (53) 29 (47)
Bp-MRI foci/patient, n, median (range) 2 (0-3) 2 (0-4) 2 (0-4)
Bp-MRI-bx/patient, n, median (range) 2 (0-3) 2 (0-4) 2 (0-4)
TRUS-bx/patient, n, median (range) 10 (10-11) 10 (2-10) 10 (2-11)
Total bx/patient, n, median (range) 12 (10-14) 12 (4-16) 12 (4-16)
Overall Gleason score, n %)
≤ 6 13 (30)
7 22 (51)
≥ 8      8 (19)
bp = biparametric; bx = biopsy; PSA = prostate-specific antigen; PSAD = PSA density; TRUS = transrectal ultrasound. 
a) Wilcoxon rank sum test comparing the negative and positive prostate cancer population.  
Demographic data. 
tablE 2
 
bp-mRi-bx
standard  
tRUs-bx
standard tRUs-bx 
+ bp-mRi-bx
Gleason score
3 + 3   7 14 13
3 + 4   6 16 14
4 + 3   7   6   8
≥ 8 12   6   8
Prostate cancer
Insignificant   4   7   6
Significant 28 35 37
Overall Gleason scores  
for standard transrectal 
ultrasound biopsy (TRUS-
bx), biparametric (bp)  
MRI biopsy cores and a 
combination of both.  
The values are n.
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a good correlation with both the number of positive bi-
opsies and their GS. Higher PI-RADS risk group was asso-
ciated with a higher likelihood of positive biopsies. Dis-
tribution of positive and negative biopsies and LG, IG 
and HG PCa in relation to PI-RADS scores for both zones 
is presented in Figure 1A and B, respectively. The rate of 
positive biopsies from PI-RADS 4 and 5 lesions was in the 
transition zone (TZ); 20% and 47% and for the peripheral 
zone (PZ) 68% and 82%, respectively.
discUssiOn
Our results confirm that bp-MRI-guided biopsies can de-
tect clinically significant PCa and may improve the diag-
nosis of biopsy-naive men. Addition of bp-MRI-guided 
biopsies to the standard TRUS-bx upgraded more pa-
tients to a higher PCa risk group with potential conse-
quences for the choice of treatment. However, bp-MRI-
bx missed clinically significant PCa in 19% according to 
the criteria. These missed PCa lesions were either GS = 7 
(3 + 4) cancers (n = 2) or high-volume (≥ 3 positive core) 
GS 6 lesions (n = 5). GS 6 lesions are harder to detect on 
MRI and are therefore more often missed [10]. How-
ever, all patients with a high-grade (GS ≥ 8) PCa lesion 
were detected and a bp-MRI led to an overall GS up-
grade in six patients. Thus, combining bp-MRI-bx with 
TRUS-bx in the examination of biopsy-naive men seems 
to decrease the risk of missing severe malignancy in the 
first round of biopsies.
Our findings are in line with other studies showing 
that the use of MRI-guided biopsies in combination with 
TRUS-bx leads to an improved detection of intermediary 
and high-risk PCa [5-7]. Especially lesions located anter-
iorly are more frequently missed by standard TRUS-bx, 
but subsequently detected by MRI-guided biopsies both 
in patients with prior negative TRUS-bx and biopsy-naive 
patients [11-13]. Although these studies used mp-MRI, 
we expected similar results using bp-MRI-guided biop-
sies as a recent retrospective study concluded that bp-
MRI is comparable with mp-MRI in detection of PCa [14]. 
If these anterior lesions were detected by bp-MRI-bx 
during the first round of biopsies, an early and more ef-
fective treatment from day one would be ensured, while 
lowering the biopsy burden by possibly avoiding several 
negative rounds of TRUS-bx. However, we had no such 
cases and a larger study is warranted to answer this 
question. 
The ESUR recommends an mp-MRI as state of the 
art in the work-up of PCa. Mp-MRI includes additional 
coronal and sagittal T2W sequences and an axial T1W 
fat-saturated DCE sequence with a total examination 
time of 60 minutes compared with bp-MRI. A T1W fat-
saturated sequence is useful in detection of blood prod-
ucts after TRUS-bx that might otherwise hinder correct 
MRI diagnosis. In a biopsy-naive population, however, 
the usefulness is limited. DCE is recommended in the 
evaluation of the peripheral zone when distinguishing 
between PI-RADS 3 and 4 lesions, where it has been 
shown to improve diagnostics [15]. However, PI-RADS 3 
lesions were also biopsied at our institution. Thus, the 
tablE 3
A cross-table of Gleason scores (GS) of standard transrectal ultrasound biopsy and biparametric (bp) 
MRI-guided biopsies. The values are n.
standard transrectal ultrasound biopsy
bp-mRi-guided biopsies negative gs = 3 + 3 gs = 3 + 4 gs = 4 + 3 GS ≥ 8
Negative 0 9 2 0 0
GS = 3 + 3 0 4 3 0 0
GS = 3 + 4 0 1 5 0 0
GS = 4 + 3 1 0 5 1 0
GS ≥ 8 0 0 1 5 6
FigURE 1
Percentage of positive, inflammation and no appreciable disease for 
Prostate Imaging Reporting and Data System scores of magnetic reso-
nance imaging lesions (a) and distribution of Gleason score risk groups 
for Prostate Imaging Reporting and Data System scores of lesions (b). 
100
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PI-RADS score
%
A
n = 3
n = 3
n = 4
n = 3
n = 8
n = 14
n = 21
n = 10
n = 14
n = 25
n = 2
n = 10
100
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3 4 5
PI-RADS score
%
B
n = 1
n = 2
n = 1
n = 2
n = 2
n = 13
n = 6
n = 15
n = 7
n = 3
IG HG
NAD Inﬂammation Positive
HG = high grade; IG = intermediary grade; LG = low grade; MRI = mag-
netic resonance imaging; NAD = no applicable disease; PI-RADS = Pros-
tate Imaging Reporting and Data System.
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distinction between PI-RADS lesion 3 and 4 was of lim-
ited importance. Bp-MRI also has the obvious disadvan-
tage of including the axial plane only. Evaluation of  
extraprostatic extension, vesiculae seminales and the 
urethra is therefore insufficient, and a bp-MRI cannot be 
used for staging. A regular staging mp-MRI examination 
should be performed subsequently if needed. However, 
a mp-MRI would be an expensive and time-consuming 
examination if used in all newly referred patients with 
suspicion of PCa. A bp-MRI seems to be sufficient to 
guide biopsies in combination with TRUS-bx in biopsy-
naive men and halves total examination time.
PI-RADS scores of lesion areas were associated with 
both the number of positive bp-MRI-bx and with histo-
logical GS in the present study. There was a direct corre-
lation with higher PI-RADS scores and the likelihood of a 
positive biopsy with a greater risk of severe malignancy 
(Figure 1). Despite the fact that bp-MRI does not include 
DCE T1W and coronal and sagittal T2W sequences, we 
found this correlation to be largely consistent with other 
studies using mp-MRI [11, 16, 17] and PI-RADS version 1 
scoring. However, the detection rate of PCa in high-risk 
PI-RADS lesions was lower than would be expected from 
the literature, especially in the TZ [11, 16, 17]. Our rela-
tively high rate of false positive evaluations in the TZ 
may be explained by the lack of coronal and sagittal 
T2W images, which makes it difficult to identify a lesion 
capsule. Several imaging planes allow an easier for dif-
ferentiation of PCa lesions from benign prostate hyper-
plasia. Lack of experience interpreting bp-MRI and ap-
prehension of missing significant PCa may also play a 
part. However, our study demonstrates the feasibility of 
the PI-RADS version 2 scoring system in the PZ adjusted 
to a bp-MRI protocol, while the TZ remains an obstacle. 
As part of the evaluation of a biopsy-naive population,  
a number of PI-RADS score 2 lesions (n = 10) were biop-
sied to confirm the absence of PCa. Even though target-
ing these lesions was inconsistent with the PI-RADS 
guidelines, it was necessary to evaluate the possibility of 
false negative lesions on bp-MRI.
Our study has some limitations; primarily the small 
population size may might explain the unusually high de-
tection rate (69%) on first-time biopsy compared with 
other studies [13, 18, 19]. Furthermore, the population 
has a selection bias due to the pilot project format that 
changes the usual working procedure and does not re-
cruit patients consecutively. In addition, no inter- or in-
traobserver variation of PI-RADS scoring was performed. 
We also experienced a few cases of MRI motion arte-
facts that complicated evaluation; we did not use spas-
molytica as is recommended for mp-MRI [8]. 
It is important to emphasise that out results are 
preliminary and indicative. However, implementing bp-
MRI-guided biopsies in combination with standard 
TRUS-bx as part of the routine examination in patients 
with suspicion of PCa has the potential to improve de-
tection of more aggressive PCa. In a population where 
the burden of PCa and the need for early diagnosis 
seems to increase, bp-MRI could be an important add-
ition to risk stratification. Larger studies are needed to 
evaluate its potential as a screening tool to exclude ag-
gressive disease and possibly avoid biopsies.
cOnclUsiOns
Bp-MRI-guided biopsies in combination with TRUS-bx up-
grade more PCa patients to a higher risk group with po-
tential consequences for the choice and effectiveness of 
their treatment. A larger prospective study with a longer 
follow-up period designed to assess the future role of  
bp-MRI in biopsy-naive men is strongly warranted.
cORREsPOndEncE: Mads Dochedahl Winther.  
E-mail: sfc113@alumni.ku.dk
accEPtEd: 27 January 2017
cOnFlicts OF intEREst: Disclosure forms provided by the authors are 
available with the full text of this article at www.danmedj.dk
litERatURE
1. Meyer MS, Mucci LA, Andersson S-O et al. Homogeneous prostate cancer 
mortality in the Nordic countries over four decades. Eur Urol 2010;58:427-
32.
2. Epstein JI, Feng Z, Trock BJ et al. Upgrading and downgrading of prostate 
cancer from biopsy to radical prostatectomy: incidence and predictive 
factors using the modified Gleason grading system and factoring in tertiary 
grades. Eur Urol 2012;61:1019-24.
3. Djavan B, Ravery V, Zlotta A et al. Prospective evaluation of prostate 
cancer detected on biopsies 1, 2, 3 and 4: When should we stop? J Urol 
2001;166:1679-83. 
4. Ukimura O, Coleman JA, de la Taille A et al. Contemporary role of system-
atic prostate biopsies: indications, techniques, and implications for patient 
care. Eur Urol 2013;63:214-30. 
5. Peltier A, Aoun F, Lemort M et al. MRI-targeted biopsies versus systematic 
transrectal ultrasound guided biopsies for the diagnosis of localized 
prostate cancer in biopsy naïve men. Biomed Res Int 2015;2015:571708.
6. Pokorny MR, de Rooij M, Duncan E et al. Prospective study of diagnostic 
accuracy comparing prostate cancer detection by transrectal ultrasound-
guided biopsy versus magnetic resonance (MR) imaging with subsequent 
mr-guided biopsy in men without previous prostate biopsies. Eur Urol 
2014;66:22-9. 
7. Abd-Alazeez M, Kirkham A, Ahmed HU et al. Performance of multi-
parametric MRI in men at risk of prostate cancer before the first biopsy: a 
paired validating cohort study using template prostate mapping biopsies 
as the reference standard. Prostate Cancer Prostatic Dis 2014;17:40-6. 
8. Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR guidelines 
2012. Eur Radiol 2012;22:746-57. 
9. Weinreb JC, Barentsz JO, Choyke PL et al. PI-RADS Prostate Imaging – 
Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. 
10. De Visschere PJL, Naesens L, Libbrecht L et al. What kind of prostate 
cancers do we miss on multiparametric magnetic resonance imaging? Eur 
Radiol 2016;26:1098-107. 
11. Boesen L, Noergaard N, Chabanova E et al. Early experience with 
multiparametric magnetic resonance imaging-targeted biopsies under 
visual transrectal ultrasound guidance in patients suspicious for prostate 
cancer undergoing repeated biopsy. Scand J Urol 2015;49:25-34. 
12. Rais-Bahrami S, Siddiqui MM, Vourganti S et al. Diagnostic value of 
biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-
specific antigen (PSA)-based detection of prostate cancer in men without 
prior biopsies. BJU Int 2015;115:381-8. 
13. Delongchamps NB, Peyromaure M, Schull A et al. Prebiopsy magnetic 
reso nance imaging and prostate cancer detection: comparison of random 
and targeted biopsies. J Urol 2013;189:493-9. 
14. Thestrup KCD, Logager V, Balslev I et al. Biparametric versus multi param-
etric MRI in the diagnosis of prostate cancer. Acta Radiol Open 2016;5: 
2058460116663046. 
15. Li C, Chen M, Li S et al. Detection of prostate cancer in peripheral zone: 
comparison of MR diffusion tensor imaging, quantitative dynamic 
contrast-enhanced MRI, and the two techniques combined at 3.0 T. Acta 
Radiol 2014;55:239-47. 
16. Roethke MC, Kuru TH, Schultze S et al. Evaluation of the ESUR PI-RADS 
 6  da n i s h m E d i c a l J O U R n a l Dan Med J 64/5  May 2017
scoring system for multiparametric MRI of the prostate with targeted MR/
TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 2014;24:344-52.
17. Renard-Penna R, Mozer P, Cornud F et al. Prostate imaging reporting and 
data system and likert scoring system: multiparametric MR imaging valid-
ation study to screen patients for initial biopsy. Radiology 2015;275:458-
68. 
18. Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance imaging 
before initial biopsy: comparison of magnetic resonance imaging-targeted 
and systematic biopsy for significant prostate cancer detection. BJU Int 
2011;108:E171-E178. 
19. Acar Ö, Esen T, Çolakoğlu B et al. Multiparametric MRI guidance in first-
time prostate biopsies: what is the real benefit? Diagn Interv Radiol 
2016;21:271-6. 
